If approved, crovalimab would be the first monthly subcutaneous treatment for patients with PNH, with the option to self-administer outside of a supervised healthcare setting.
Tag Archive for: crovalimab
Data from the Phase III COMMODORE 2 study show Roche-subsidiary Genentech’s investigational antibody crovalimab is non-inferior to AstraZeneca’s Soliris (eculizumab), the current standard of care in paroxysmal nocturnal hemoglobinuria (PNH).
